Actionable news
0
All posts from Actionable news
Actionable news in PYPL: PAYPAL HOLDINGS Inc COMMON STOCK,

Jim Cramer — Will FDA Approve Sarepta's Duchenne Drug After All?

Shares of Sarepta Therapeutics (SRPT - Get Report) are soaring 20% Thursday on a report the company could win Food and Drug Administration drug approval after all for its Duchenne muscular dystrophy drug.

A recent panel recently gave a negative review (as chronicled by TheStreet's Adam Feuerstein), but that doesn't necessarily mean it's a done deal, according to Jim Cramer, the co-manager of the Action Alerts PLUS portfolio.

Dr. Janet Woodcock is the FDA's top drug evaluator, and met with some of the families of the...


More